BioCentury
ARTICLE | Finance

VCs need not apply

With a new Astellas deal, Affinivax can forgo VC funding as it builds its pipeline

March 4, 2017 1:48 AM UTC

After sealing its second deal with Astellas Pharma Inc. (Tokyo:4503) last week, Affinivax Inc. says it can continue to build its pipeline without any venture money.

Founded in 2014, the vaccine company has sustained itself on $6.5 million in seed money from the Bill & Melinda Gates Foundation and an undisclosed amount of non-dilutive funding from partnerships with not-for-profit PATH as well as Nosocomial Vaccine Corp. (NVC), a JV between Astellas and the ClearPath Development Co. subsidiary of RRD International LLC. ...

BCIQ Company Profiles

Affinivax Inc.